English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Thursday, July 18, 2019
Eisai Presents Research Evaluating Correlation of Highly-Precisely Measured Amyloid Beta in Plasma and Cerebrospinal Fluid with Newly Developed Automated Protein Assay System at AAIC 2019
Eisai Presents Nonclinical Research Results of Elenbecestat at AAIC 2019
Wednesday, July 17, 2019
エーザイ、抗がん剤「ハラヴェン(R)」が局所進行性または転移性乳がんに係る適応で中国当局より承認を取得
Wednesday, June 13, 2018
エーザイ、新規の核酸合成とデリバリー技術を用いた核酸創薬研究に関する産学官共同研究開発契約を締結し、研究活動を開始
Wednesday, July 17, 2019
Eisai's Anticancer Agent Halaven Approved for Treatment of Locally Advanced or Metastatic Breast Cancer in China
Thursday, July 11, 2019
Eisai Listed for 18th Consecutive Year in FTSE4Good Index Series
Latest Data on Eisai's Alzheimer's Disease/ Dementia Pipeline to be Presented at AAIC 2019
エーザイ、社会的責任投資指数「FTSE4Good Index Series」の対象銘柄に18年連続で選定
エーザイ、アルツハイマー病協会国際会議2019(AAIC2019)においてアルツハイマー病/認知症領域の開発品に関する最新データを発表
Wednesday, July 10, 2019
エーザイ、全く新しい創薬アプローチによる革新的認知症治療薬の創出をめざすG2D2が米国マサチューセッツ州ケンブリッジにおいて本格稼働

Copyright © 2025 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575